Micromet, Inc. (MITI)

negative independent ratings. eps est are being lowered. charts showing a strong downward trend. big insider selling...CFO sold all his positions.

Pullback Likely on Relatively Weak Stock

Innovative technology, using antibodies to make the immune system attack cancer cells could be a major breakthrough, plus they have had positive results in clinical trials

their patented safe antibody platform will change the standard in treatment of cancer. they are going to create a royality system of revenues sold throughout the pharma industry. in 10 years , heres another 10 bagger.
Dr. D

4.5 and above is strong resistance in the near term.

MITI has a too high valuation compared to its sales potential. It is also one of the most loss making companies.

- Forecasted Earnings per Share of $-0.73 per share
- P/E of of -4.82
- Earnings Yield of -20.74 percent
- Growth to P/E Ratio of -0.20

bad company ready to go down

Highly Overpriced with nothing but negative returns!

Listen carefully: This stock will be at $20 on or around December 6th-9th. These dates are the 50th ASH meeting where MITI will present phae II data from its drug MT203. If results are positive, the stock will soar. So far, results have been close to 100% positive. December will be the time of the catalyst. Get in before its too late. Good Luck

The worst company on earth.

Hope I'm not too late on this one....

Riding down

I've been in MITI since Dec 07. Potential of BITE is amazing and although MT103 is their lead candidate, they have many BITE platforms in development.

Check out the Science Magazine article that just rocketed the stock into the high 5's (as high as 6.50. Listen to the company CC that was predicated on the Science Magazine article. Check out the Science Advisory Board panel mambers that MITI stood up a a steering committee for their pending products.

7 of 7 patients tested at the highest doses (which are 5 orders of magnitude lower than existing antibody therapies) showed complete or partial remission. Longest treated candidate is still in remission over a year later.

Even though the stock has moved significantly this year, if the additional data which will be released in Dec at ASCO continues to show promise, the stock will continue to move up sharply.

cancer research should provide valuable results and may end some forms of cancer

Small German biotech company working on BiTE (Bispecific T Cell Engagers) technology. They published a phase I study on the use of a CD3 and CD19 small partial antibody 'mix'. The NHL patients treated in this study had very very impressive response rates with extremly low doses in this early phase I study. Long term infusions were used are very logical in the context of this relatively small molecule. The clinical side effects are what you would expect and almost hope for to signal immun activation.

Very impressive technology that might solve the BiTE problems with smaller partial antibodies.

Exciting: very very exciting! I'm in big time. Just to bad I haden't heard about them a few months ago. Just hard to follow so many small biotech companies. Hope their stock price goes down a bit so I could get more of this possibly revolutionary company.

This is one of those rare tech companies that changes all the rule or fails quickly if their technology doesn't work. It's a binary proposition with a risk/ reward I find very positive. Time will tell...

Gar-bage!

zzlagerhans wise advice.